LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Toxoplasmosis Immune Status in Pregnancy Determined by Immunochromatography Assay

By LabMedica International staff writers
Posted on 30 Mar 2021
Print article
Image: TOXOPLASMA ICT IgG-IgM is a unitary qualitative rapid test based on the immune chromatography technology (lateral flow), allowing the simultaneous detection of both IgG and IgM class anti-Toxoplasma antibodies in human sera (Photo courtesy of LDBIO DIAGNOSTICS)
Image: TOXOPLASMA ICT IgG-IgM is a unitary qualitative rapid test based on the immune chromatography technology (lateral flow), allowing the simultaneous detection of both IgG and IgM class anti-Toxoplasma antibodies in human sera (Photo courtesy of LDBIO DIAGNOSTICS)
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite, one of the world's most common parasites. Infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy.

Obstetrical toxoplasmosis involves the systematic serological screening for Toxoplasma‐specific IgG and IgM antibodies which is usually performed using enzyme-linked immunosorbent assay (ELISA) techniques. Screening tests used routinely are not sufficient and require additional techniques to determine the Toxoplasma immune status.

Medical Parasitologists at the Pasteur Institute of Tunis (Tunis, Tunisia) selected 39 sera collected during the period 2015 to 2018 in the setting of the routine Toxoplasma serological screening in pregnant women. Sera were selected according to their anti‐Toxoplasma IgM and IgG antibodies titers in “Platelia Toxo IgG, IgM” (Bio-Rad, Marnes-la-Coquette, France).

Western blot Toxo II IgG (LDBIO DIAGNOSTICS, Lyon, France) was performed for all the sera in order to precisely determine their exact Toxoplasma immune status. The LDBIO Toxoplasma ICT IgG‐IgM is a rapid, simple, qualitative test based on immunochromatography technology (ICT, lateral flow). A positive test reveals the presence of anti‐Toxoplasma antibodies, but does not distinguish between IgG and IgM classes.

The scientists reported that in the absence of IgM and presence of IgG equivocal titers in ELISA, Toxoplasma ICT IgG‐IgM and WB Toxo II results were 94.7% concordant. All positive samples in WB were also positive in ICT. The sensitivity in the detection either of low IgG titers in absence of IgM or of specific anti‐Toxoplasma IgM was 100%. Only one serum with equivocal IgG titer by ELISA and negative with Toxo II IgG test revealed positive in ICT. However, this serum showed a P30 band in WB analysis. On the other hand, three sera positive in ELISA IgM and negative in ELISA IgG revealed positive in ICT and negative in WB Toxo II IgG, the reference test.

The authors concluded that their results confirm the high sensitivity of Toxoplasma ICT IgG‐IgM in detecting both specific anti‐Toxoplasma IgG and IgM, and highlight the usefulness of this rapid test as a first or second‐line Toxoplasma serological test in pregnant women. The study was published on March 15, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Pasteur Institute of Tunis
Bio-Rad
LDBIO DIAGNOSTICS


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more